Arena’s Belviq Launch Outpaces Vivus’s Qsymia

by Andrew Berens, MD and Thomas Smith, Bloomberg Industries

Prescriptions of Arena/Eisai’s Belviq for obesity appear strong compared to competitor Vivus’ Qsymia. Prescriptions of Belviq rose 83 percent to 2,162 in its second full week on the market, according to data from Symphony Health. Qsymia did not reach this level until its fifth full week.

Read more>>> 

Bloomberg BRIEF Newsletters